Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Carla Verena Hannig
Neoadjuvant Chemotherapy With Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results After a Median Follow-Up of Over 4 Years
Breast Care
Surgery
Oncology
Related publications
Effectiveness of Neoadjuvant Trastuzumab and Chemotherapy in HER2-overexpressing Breast Cancer
Journal of Cancer Research and Clinical Oncology
Medicine
Cancer Research
Oncology
Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
New England Journal of Medicine
Medicine
Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Predicting Successful Conservative Surgery After Neoadjuvant Chemotherapy in Hormone Receptor-Positive, HER2-Negative Breast Cancer
Journal of Breast Disease
Clinical Experience of Dual Targeted Blockade (Pertuzumab + Trastuzumab + Docetaxel) in Neoadjuvant Therapy of Early HER-2-Positive Breast Cancer
Effective Pharmacotherapy
Efficacy of Neoadjuvant Therapy With Trastuzumab Concurrent With Anthracycline- And Nonanthracycline-Based Regimens for HER2-positive Breast Cancer
Cancer
Cancer Research
Oncology
Pcn74 - A Budget-Impact Analysis of Adjuvant Pertuzumab and Trastuzumab in Early Her2-Positive Breast Cancer
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
New England Journal of Medicine
Medicine
T-Bet Expression in Intratumoral Lymphoid Structures After Neoadjuvant Trastuzumab Plus Docetaxel for HER2-overexpressing Breast Carcinoma Predicts Survival
British Journal of Cancer
Cancer Research
Oncology
